Monopar Therapeutics (MNPR) stock
MNPRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$70.75−0.31 (-0.44%)
Close on Nov 18, 2026Market cap $474.89MP/E –Yield –
Monopar Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Monopar Therapeutics's revenue for the twelve months ending Dec 31, 2019 was $0. For fiscal 2025 it was $0. The highest annual figure on record is $0 in fiscal 2016.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | – |
| FY2024 | Dec 31, 2024 | $0 | – |
| FY2019 | Dec 31, 2019 | $0 | – |
| FY2018 | Dec 31, 2018 | $0 | – |
| FY2017 | Dec 31, 2017 | $0 | – |
| FY2016 | Dec 31, 2016 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $0 | – |
| Q1 FY2026 | Mar 31, 2026 | $0 | – |
| Q4 FY2019 | Dec 31, 2019 | $0 | – |
| Q3 FY2019 | Sep 30, 2019 | $0 | – |
| Q2 FY2019 | Jun 30, 2019 | $0 | – |
| Q1 FY2019 | Mar 31, 2019 | $0 | – |
| Q4 FY2018 | Dec 31, 2018 | $0 | – |
| Q3 FY2018 | Sep 30, 2018 | $0 | – |
| Q2 FY2018 | Jun 30, 2018 | $0 | – |
| Q1 FY2018 | Mar 31, 2018 | $0 | – |
| Q4 FY2017 | Dec 31, 2017 | $0 | – |
| Q3 FY2017 | Sep 30, 2017 | $0 | – |
| Q2 FY2017 | Jun 30, 2017 | $0 | – |
| Q1 FY2017 | Mar 31, 2017 | $0 | – |
See a number that looks wrong?